alexa
Reach Us +44-7482878454
HIV Co-Infections with Hepatitis B and C | OMICS International | Abstract
ISSN 2155-6113

Journal of AIDS & Clinical Research
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

HIV Co-Infections with Hepatitis B and C

Ekachai Singhatiraj, Joshan Suri and Claudia Goulston*

Division of Infectious Diseases, University of Utah, Salt Lake City, UT, USA

*Corresponding Author:
Claudia Goulston
Division of Infectious Diseases
University of Utah, Salt Lake City, UT, USA
E-mail: [email protected]

Received Date: December 01, 2011; Accepted Date: January 16, 2012; Published Date: January 20, 2012

Citation: Singhatiraj E, Suri J,Goulston C (2012) HIV Co-Infections with Hepatitis B and C. J AIDS Clinic Res S3:001. doi:10.4172/2155-6113.S3-001

Copyright: © 2012 Singhatiraj E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Abstract

With the introduction of highly active antiretroviral therapy (HAART), Human Immunodeficiency Virus (HIV) infected patients live longer and many have co-infections with chronic hepatitis B (HBV) or hepatitis C (HCV) that complicates their care. Treatment of HBV and HCV in the HIV positive co-infected patient requires careful consideration of the timing of initiation of HAART treatment, drug-drug interactions and drug and immune effects. It is an exciting era due to the introduction of new medications available to treat both HBV and HCV infections. Knowledge of the complex interactions between these viruses as well as the effect of various treatment modalities on each virus is the key to understanding and treating these patients effectively

Top